Free Trial
NASDAQ:CLSD

Clearside Biomedical Q2 2025 Earnings Report

Clearside Biomedical logo
$0.37 -0.02 (-5.14%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.37 +0.00 (+0.14%)
As of 08/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Clearside Biomedical Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$8.00 thousand
YoY Revenue Growth
N/A

Clearside Biomedical Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Clearside Biomedical's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Clearside Biomedical Earnings Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Clearside Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email.

About Clearside Biomedical

Clearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

View Clearside Biomedical Profile

More Earnings Resources from MarketBeat